SLC5A2 and metabolic dysfunction-associated steatohepatitis: NASH/NAFLD patients with T2D should be preferentially treated with novel drugs licensed for diabetes treatment such as GLP-1RA and SGLT2 inhibitors [120], because these agents also have hepatoprotective [146] and nephroprotective efficacy [119,131].